News

In two Phase 3 trials for the treatment of CDI, fidaxomicin was non-inferior in clinical cure when compared to vancomycin, the only FDA approved product for CDI. The

As per the terms of the research collaboration and option agreement, Pepscan will utilize its Chemical LInkage of Peptides onto Scaffolds (CLIPS) technology for optimizing novel therapeutic Phylomer

The company is engaged in the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of functional proteomics, drug development and development of biomarkers.

Regorafenib is indicated as a treatment for patients who are suffering from metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and

Typical applications range from small-scale protein expression to media or process optimization studies UniVessel SU is made up of USP class VI conform polycarbonate and is suitable for

The company has reported a net loss of $1.22m, or $0.02 loss per diluted share, compared to net loss of $1.05m or $0.02 loss per diluted share, for

The company has reported a net income was $6.48m, or $0.02 per diluted share, compared to a net loss of $3.15m, or $0.02 loss per diluted share, for

The study results suggested that the adult patients evaluated with Cimzia that achieved early responses were found to have an increased chance of achieving longer-term outcomes. In the

The company has reported a net loss of $1.38m, or $0.02 loss per diluted share, compared to net loss of $1.61m or $0.02 loss per diluted share, for